Clinical trials for Acute myeloid leukemia
35 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT07493538MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological DiseasesMasonic Cancer Center, University of Minnesota
- RECRUITINGPhase 2NCT07392242A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center · PI: Kuo-Kai Chin, MD
- RECRUITINGPhase 3NCT07075016Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive ChemotherapyStichting Hemato-Oncologie voor Volwassenen Nederland
- RECRUITINGPhase 1NCT06649227Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19University Hospital, Lille · PI: Ibrahim Yakoub-Agha, MD,PhD
- RECRUITINGN/ANCT07237230Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid LeukemiaDonghua Zhang
- RECRUITINGPHASE1, PHASE2NCT06969430A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)Debiopharm International SA
- RECRUITINGNCT06899581Gut Health in Children With CancerGreat Ormond Street Hospital for Children NHS Foundation Trust
- RECRUITINGPhase 2NCT06783790Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTInstitute of Hematology & Blood Diseases Hospital, China · PI: Erlie Jiang
- RECRUITINGEarly Phase 1NCT06762132A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid LeukemiaZhejiang University · PI: He Huang, MD
- RECRUITINGPhase 1NCT06514261Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AMLNational Cancer Institute (NCI) · PI: Annie P Im
- RECRUITINGPhase 2NCT06635681Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AMLInstitute of Hematology & Blood Diseases Hospital, China · PI: Hui Wei, MD
- RECRUITINGPhase 2NCT06529731Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell TransplantationSawa Ito, MD · PI: Sawa M Ito, MD, PhD
- RECRUITINGNCT06510868Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide TherapyUniversity Health Network, Toronto
- RECRUITINGPHASE1, PHASE2NCT06235801A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid LeukemiaM.D. Anderson Cancer Center · PI: Nicholas Short, MD
- RECRUITINGNCT06297551Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)Suhu Liu · PI: Suhu Liu, MD PhD
- RECRUITINGN/ANCT07062250Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid LeukemiaRigshospitalet, Denmark · PI: Lars Kjeldsen, MD
- RECRUITINGPhase 1NCT06731699A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDSChengdu FenDi Pharmaceutical Co., Ltd.
- ACTIVE NOT RECRUITINGPhase 2NCT06268574Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AMLRyvu Therapeutics SA
- RECRUITINGPhase 2NCT06022003Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid LeukemiaFrench Innovative Leukemia Organisation
- RECRUITINGPhase 2NCT06191263Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AMLRyvu Therapeutics SA
- RECRUITINGNCT05909501Assessment of Geriatric Evaluations Impact on New AML GuidanceAbramson Cancer Center at Penn Medicine · PI: Catherine Lai, MD
- RECRUITINGPhase 2NCT06046313Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDSFirst Affiliated Hospital of Zhejiang University · PI: Weiyan Zheng, MD
- ACTIVE NOT RECRUITINGPhase 4NCT06041529Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential HypertensionYuhan Corporation · PI: Sanghyun Ihm
- RECRUITINGPhase 2NCT06084819Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaChinese PLA General Hospital · PI: Daihong Liu, doctor
- RECRUITINGPhase 2NCT05805605Allo HSCT Using RIC and PTCy for Hematological DiseasesMasonic Cancer Center, University of Minnesota · PI: Mark Juckett
- ACTIVE NOT RECRUITINGPhase 1NCT05396859Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid LeukemiaOHSU Knight Cancer Institute · PI: Ronan T Swords, M.D.
- RECRUITINGNCT05304156Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study"Assistance Publique - Hôpitaux de Paris
- ENROLLING BY INVITATIONNCT05332054Long-Term Follow-up StudyCaribou Biosciences, Inc.
- RECRUITINGPHASE1, PHASE2NCT05010122ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · PI: Farhad Ravandi-Kashani
- RECRUITINGPHASE1, PHASE2NCT04385290Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)Technische Universität Dresden · PI: Christoph Röllig, Prof. Dr.
- ACTIVE NOT RECRUITINGPhase 2NCT04097470Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS PatientsStichting Hemato-Oncologie voor Volwassenen Nederland · PI: Gerwin Huls, Prof
- ACTIVE NOT RECRUITINGPhase 1NCT03679650Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML PatientsBeth Israel Deaconess Medical Center · PI: Jacalyn Rosenblatt, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03603795Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction ChemotherapyFrench Innovative Leukemia Organisation · PI: Arnaud PIGNEUX, MD PD
- ACTIVE NOT RECRUITINGPhase 2NCT02782546Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell TransplantationWashington University School of Medicine · PI: Amanda Cashen, M.D.
- RECRUITINGNCT01890486The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative RegimenWake Forest University Health Sciences · PI: Dianna Howard, MD